Full-Time

Supervisor

Insurance Verification

Posted on 1/22/2025

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions

Biotechnology
Healthcare

Compensation Overview

$65k - $85kAnnually

Junior, Mid

Company Historically Provides H1B Sponsorship

Remote in USA

Category
Insurance
Finance & Banking

You match the following Natera's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree or equivalent experience.
  • Minimum of 2 years directly related and progressively responsible experience.
  • 2+ years of Lead and/or supervisory experience.
  • Experience with insurance claims submission and management software.
Responsibilities
  • Supervise team including monitoring production and quality to specified goals.
  • Assists with feedback for hiring, discipline and performance evaluations.
  • Oversees the process of providing coverage for production environment.
  • Provides department orientation for all direct reports and coordinates training per job description.
  • Ensures that on-going training is provided for established employees, including the development & maintenance of standard operating procedures.
  • Liaisons with internal departments to promote ongoing communication and ensure accuracy.
  • Acts as an escalated level of response for concerns and complaints.
  • Assists staff with enforcing policy.
  • Works with cross functionally to manage the entire process from insurance verification to final collection.
  • Monitors and validates adherence to policies and procedures, auditing as necessary.
  • Completes projects and reports in a timely fashion on a daily, weekly or monthly basis per the direction of management.
  • Develops, monitors, coaches, and manages staff, ensuring the development of employees through orientation, training establishing objectives, communication of rules, constructive discipline.
  • Promotes a positive working environment through role modeling, team development, respect, and being fair and consistent.
Desired Qualifications
  • Thorough knowledge of healthcare reimbursement environment (government and private payers) including coverage, coding and payment and understanding of insurance billing practices.
  • Demonstrated ability to develop and analyze payments, diagnose issues, and present findings to management.
  • Must be able to communicate effectively both orally and in writing. Strong interpersonal skills.
  • Strong organizational skills; attention to detail.
  • Ability to proficiently use computer and standard office equipment.
  • Working knowledge of Microsoft Office.
  • Previous experience with Google Enterprise Suite – Gmail, Slides, Sheets, Docs, Drive.
  • Knowledge of payer eligibility and benefits. Health care research and analysis skills sufficient to support payer research healthcare policy library and state management.
  • Conflict resolution skills. Must be able to resolve employee issues effectively and efficiently.

Natera specializes in genetic testing and diagnostics, focusing on advanced testing solutions for various medical needs. Their main technology is cell-free DNA (cfDNA) testing, which analyzes small DNA fragments in the blood to detect molecular residual disease (MRD) in cancer patients, aiding in treatment decisions. They also offer the Signatera test, a custom ctDNA test for cancer patients, accessible through their GI Expanded Access Program. In addition to oncology, Natera provides testing for organ health in transplant patients and offers a range of women's health tests, including the Panorama NIPT for prenatal screening. Natera's services are provided to healthcare providers, hospitals, and directly to patients, generating revenue through testing kits and services, often reimbursed by insurance. Their goal is to enhance patient care through precise genetic insights and support.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • AI integration enhances accuracy and speed of Natera's cfDNA analysis.
  • Growing personalized medicine trend aligns with Natera's customized genetic tests.

What critics are saying

  • Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
  • New Prospera Heart features may face slow adoption by healthcare providers.
  • Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

What makes Natera unique

  • Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
  • Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
  • Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

10%
MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

Yahoo Finance
Jun 17th, 2024
Natera Launches Differentiated New Feature For Prospera(Tm) Heart Test, Enhancing Detection Of Rejection For Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection

Stock Titan
Jun 17th, 2024
Natera Launches Differentiated New Feature for Prospera(TM) Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera (NASDAQ: NTRA) has launched an enhanced version of its Prospera Heart(TM) test, integrating a Donor Quantity Score (DQS) to better detect heart transplant rejection.

ETF Daily News
May 18th, 2024
Massachusetts Financial Services Co. MA Invests $27.63 Million in Natera, Inc. (NASDAQ:NTRA)

MA invests $27.63 million in Natera, Inc. (NASDAQ:NTRA).

GlobeNewswire
May 15th, 2024
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Then, on March 9, 2022, Hindenburg Research ("Hindenburg") issued an investigative report (the "Hindenburg Report") alleging, among other things, that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."

Business Wire
May 3rd, 2024
New Natera Publication Bolsters Evidence For Extended Surveillance With Signatera™ In Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here. The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS). Patients were followed for up to 12 years after surgery and adjuvant chemotherapy, with blood samples collected semi-annually and then analyzed using Signatera. Key findings include:Signatera detected relapse up to 38 months earlier than imaging (median lead time 10.5 months), with an overall sensitivity of 88.2% (30/34)Relapse-free survival (RFS) and overall survival (OS) were significantly worse in patients who were ctDNA-positive, regardless of hormone receptor and HER2 subtype (HR 52.98 and 53.69, respectively)

Business Wire
May 1st, 2024
Natera Launches Fetal Rhd Nipt Supporting Ob/Gyn Physicians And Patients During Rhig Shortage

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg). Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants. The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology. Up to 15 percent of pregnant patients are RhD-negative1

BioSpace
May 1st, 2024
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

AUSTIN, Texas-(BUSINESS WIRE)- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.

INACTIVE